Velocity is the world's leading integrated site organization.
Sponsors and CROs trust Velocity to deliver high-quality clinical trial data and patient care with unprecedented efficiency.
Simplify everything from site selection to study close-out
Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.
News
Potential Breakthrough to Preserve Lean Muscle Mass During GLP-1-Induced Weight Loss
The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s … Read more
Julio Rosenstock, MD Lead Author of Phase 2 Trial Results Evaluating Orforglipron Published in Diabetes, Obesity and Metabolism
Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron … Read more
Not All AI Belongs in Clinical Trials. Here’s How We Decide Which Models Do.
It’s a cliché at this point to say AI (artificial intelligence) is the future; there are people still struggling to work their smartphones who could tell you that. AI tools … Read more
Velocity Appoints Dr. Sarah Smiley as Chief Physician Officer
Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it … Read more